Articles

Nexstar-Tegna deal puts Trump move to eliminate broadcast ownership rules to the test

Nextstar is looking to buy Tegna in a $6.2 billion cash deal — but will the FCC allow it despite a conflict with current TV ownership rules?

Why the Russell 2000 has a real chance to beat the S&P 500 — finally

Small-cap stocks look primed for their big moment. But we’ve been here before.

How restaurant chains are competing on in-store vibes to win back customers

Analysts say more welcoming atmospheres at chains like Starbucks and Cava can’t hurt. But how much will they help?

Why adding private equity to your 401(k) can put your retirement on the line

Alternative-investment options may feel like progress — but they also increase the chance of confusion and costly missteps.

The U.S. jobs report has never been so under the gun. Here’s why fixing it won’t be easy.

The critical U.S. jobs report is under the hot glare of a suspicious Trump White House, but there’s no quick or easy fix for the most important economic survey in the world.

Are you willing to take big risks for big returns? You may be a newbie investor.

Newer investors tend to be more comfortable with risk than more experienced investors, according to a study by Fidelity.

Nearly 50% of adults are now ordering kids’ meals. ‘It’s economical and it’s filling.’

It seems we’re all in the mood for miniburgers and chicken fingers.

Palo Alto Networks’ earnings beat sparks investor confidence in the cybersecurity industry

The company’s strong performance last quarter points to a “bright spot” in the cybersecurity and software space.

10 questions to ask if you want to move abroad when you retire

Your answers will help determine if expat life is a good fit for you.

My stepmother’s lawyer called us ‘greedy’ for fighting for our father’s estate. When will it end?

“During the marriage, all his real estate ended up in trusts he didn’t fully understand.”

Viking Therapeutics’ stock tumbles after results of oral weight-loss drug trial. It has company.

Viking Therapeutics on Tuesday announced that a trial showed its oral weight-loss drug works — and like a larger rival, its stock price immediately suffered.

European defense stocks in retreat. Ukraine peace could derail the rally.

Prospect of peace may crimp demand in the sector that has rallied this year.
1 341 342 343 344 345 2,594